Highest-materiality recent filing
BioRestorative CEO and CFO resign; board appoints new CEO, investigates employment agreements
CEO Lance Alstodt and CFO Robert Kristal resigned July 13, 2026, claiming 'Good Reason' under alleged Change in Control; seek ~$2.85M aggregate severance plus equity acceleration.
New employment agreement for VP R&D Francisco Silva, effective June 10, 2026, with term through June 10, 2029.
Entered $1,000,000 revolving loan agreement with Bowery Group LLC at 12% interest, 16% default rate, 1-year maturity.
CEO Lance Alstodt signed 3-year employment agreement with $600k annual salary, unchanged.
BioRestorative Therapies approves 2025 executive bonuses; CEO bonus $300K, VP $287.5K, CFO $140K
CEO Lance Alstodt awarded $300K cash bonus and $1.5M in option awards; total 2025 compensation $2.4M.
BioRestorative Therapies posts updated corporate presentation; no financial details disclosed
Updated presentation made available on company website on April 23, 2026.
BioRestorative raises $5.0M in public offering of stock and warrants to fund clinical programs
Offering of 14.3M shares (or pre-funded warrants) and 14.3M five-year warrants at $0.35/unit closed Feb 13.
BioRestorative Therapies reports Q3 2025 results; press release content omitted from filing
Press release dated November 12, 2025, announced Q3 2025 financial results and business update.
Registered direct offering of 678,125 shares at $1.60/share, gross proceeds $1.085M; closing expected Oct 8, 2025.
Elected Francisco Silva (1.59M for) and David Rosa (1.47M for) as Class II directors; ~3.33M broker non-votes.
BioRestorative Therapies releases updated corporate presentation; no financial details in filing
Updated investor presentation posted on company website and furnished as Exhibit 99.1.
BioRestorative Therapies issues Q2 2025 earnings; no figures in provided excerpt
Press release dated Aug 12, 2025 announces Q2 financial results and a business update.
Preliminary blinded data from 36 subjects in Phase 2 trial of BRTX-100 for chronic lumbar disc disease presented at ISSCR 2025.
BioRestorative Therapies issues Q1 2025 results press release; financial details not available
Company announced Q1 2025 financial results and business update on May 14, 2025.
BioRestorative Therapies replaces auditor Marcum with CBIZ after Marcum attest business acquired
Marcum LLP resigned as auditor on April 16, 2025; FY2024 and FY2023 reports unqualified except FY2024 includes going-concern paragraph.
Financial results for year ended Dec 31, 2024 will be released after market close on March 27, 2025.
BioRestorative Therapies presents at ORS 2025; VP Silva discusses development programs
Francisco Silva, VP of R&D, presented at Orthopaedic Research Society 2025 Annual Meeting on Feb 8.
BioRestorative Q3 operating loss narrows 26% YoY; BRTX-100 Phase 2 data shows improvement
Q3 2024 operating loss $2.3M vs $3.1M YoY (26% improvement); net loss $1.1M ($0.13/sh).
BioRestorative to present Phase 2 BRTX-100 data at spine symposium; Q3 results call Nov 13
Additional preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 for chronic lumbar disc disease to be presented on Nov 13, 2024.
Entered ATM agreement with Rodman & Renshaw on Nov 6, 2024 for up to $3.6M of common stock.
BioRestorative shareholders approve doubling of stock incentive plan shares to 6.85M
Class I director Nickolay Kukekov re-elected with 2,050,111 votes for, 135,114 withheld, 2,048,738 broker non-votes.
BioRestorative Therapies issues Q2 2024 results press release; specific figures not provided
Press release announcing Q2 2024 financial results was issued on August 13, 2024.
BioRestorative Therapies schedules Q2 2024 earnings release and call for Aug 13
Financial results for Q2 2024 will be released after market close on Tuesday, August 13, 2024.
BioRestorative Therapies restates financials due to warrant classification error; no cash impact
Previously issued annual (FY2023) and quarterly (Q1'22–Q3'23) financial statements should no longer be relied upon.
BioRestorative receives Nasdaq notice for late 10-Q filing; no immediate delisting
Nasdaq notified BioRestorative on May 22, 2024 of non-compliance with Listing Rule 5250(c)(1) due to delinquent Form 10-Q for Q1 2024.
BioRestorative Therapies to present at 36th Annual ROTH Conference on March 18, 2024
CEO Lance Alstodt to participate in fireside chat on March 18, 2024 at 12:00pm PDT.
BioRestorative raises $8.1M via warrant exercise and new private placement warrants
Gross proceeds of $8.1M from exercise of existing warrants for 3,351,580 shares at $2.33/share.
BioRestorative reports positive preliminary Phase 2 data for BRTX-100 in chronic lumbar disc disease
Preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 presented at ORS 2024 Annual Meeting.
BioRestorative to present Phase 2 BRTX-100 data at ORS meeting, host webcast Feb 5
Preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 for chronic lumbar disc disease to be presented at ORS 2024 Annual Meeting Feb 2-6 in Long Beach.
BRTX stockholders elect directors, approve share increase, ratify auditor at annual meeting
Class III directors Lance Alstodt and Patrick F. Williams elected with 864,671 and 662,099 votes for, respectively.
BRTX prices $2.1M registered direct offering of 685,033 shares at $3.03/share
Offering of 685,033 shares at $3.03/share for gross proceeds of approximately $2.1M; closing expected July 13, 2023.
BioRestorative enters ATM equity facility with JonesTrading for up to $3.7M
Capital On Demand Sales Agreement signed April 14, 2023 with JonesTrading Institutional Services LLC.
BioRestorative Therapies files accounting firm consents for S-3 registration statement
Filed consents of Friedman LLP and Marcum LLP to incorporate audit reports into Form S-3.
BioRestorative Therapies reincorporates from Delaware to Nevada as of Dec 31, 2022
Reincorporation approved by stockholders on Nov 3, 2022; effective Dec 31, 2022 via merger of DE corp into NV subsidiary.
BioRestorative shareholders approve all proposals, including reincorporation to Nevada
Elected David Rosa and Francisco Silva as Class II directors; 1.8M and 1.95M shares for, respectively.
BioRestorative exchanges preferred shares with Auctus, replaces auditor after Friedman/Marcum merger
Issued 1,543,158 Series B preferred shares to Auctus Fund in exchange for same number of Series A shares on Sept 8, 2022.
BioRestorative Therapies enters CFO employment agreement with $175K salary, stock option grant
CFO Robert E. Kristal employment agreement effective Nov 4, 2021, term through Nov 4, 2022.
BioRestorative reduces authorized shares to 75M after 1-for-4,000 reverse split
Board approved reduction of authorized common shares from 300B to 75M, consistent with the 1-for-4,000 reverse split ratio.
BioRestorative closes $23M public offering, swaps $10M notes for equity
Closed underwritten public offering of 2.3M units at $10 each, gross proceeds ~$23M. Each unit: 1 common share + 1 warrant.
Priced underwritten public offering of 2.3M units at $10/unit for gross proceeds of $23M; net proceeds ~$20.87M.
BioRestorative Therapies announces 1-for-4,000 reverse stock split effective Oct 27
Board approved and stockholders authorized a 1-for-4,000 reverse split of common stock.
Exchanged aggregate $9,246,897 principal of convertible notes and warrants for units in proposed public offering.
BioRestorative Therapies shareholders approve reverse stock split, reject Nevada reincorporation
Elected Nickolay Kukekov as Class I director: 1.49B for, 132.6M withheld, 452M broker non-votes.
the remaining members of the Company’s Board of Directors (the “Board”) appointed Mika Grasso, Katharyn Field and Jatinder Dhaliwal (collectively, the “New Directors”), designees of the Lender, as directors of the Company.
Effective June 11, 2026, pursuant to the Revolving Loan Agreement, Francisco Silva, Nickolay Kukekov and Patrick F. Williams resigned as directors of the Company.
Effective June 11, 2026, pursuant to the Revolving Loan Agreement, Francisco Silva, Nickolay Kukekov and Patrick F. Williams resigned as directors of the Company.
Effective June 11, 2026, pursuant to the Revolving Loan Agreement, Francisco Silva, Nickolay Kukekov and Patrick F. Williams resigned as directors of the Company.
the remaining members of the Company’s Board of Directors (the “Board”) appointed Mika Grasso, Katharyn Field and Jatinder Dhaliwal (collectively, the “New Directors”), designees of the Lender, as directors of the Company.
the remaining members of the Company’s Board of Directors (the “Board”) appointed Mika Grasso, Katharyn Field and Jatinder Dhaliwal (collectively, the “New Directors”), designees of the Lender, as directors of the Company.
Effective November 4, 2021, David Rosa was elected a director of the Company.
Effective November 4, 2021, Patrick F. Williams was elected a director of the Company.
Effective November 4, 2021, Robert E. Kristal, age 54, was appointed Chief Financial Officer of the Company.
Max materiality 0.85 · Median 0.50 · Most common event other_material